Your browser doesn't support javascript.
loading
A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors.
Ren, Peng-Xuan; Shang, Wei-Juan; Yin, Wan-Chao; Ge, Huan; Wang, Lin; Zhang, Xiang-Lei; Li, Bing-Qian; Li, Hong-Lin; Xu, Ye-Chun; Xu, Eric H; Jiang, Hua-Liang; Zhu, Li-Li; Zhang, Lei-Ke; Bai, Fang.
Affiliation
  • Ren PX; School of Life Science and Technology, and Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China.
  • Shang WJ; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Yin WC; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Ge H; State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
  • Wang L; School of Life Science and Technology, and Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China.
  • Zhang XL; School of Life Science and Technology, and Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China.
  • Li BQ; School of Life Science and Technology, and Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China.
  • Li HL; Department of Chemistry, Imperial College London, London, United Kingdom.
  • Xu YC; State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai, 200237, China.
  • Xu EH; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Jiang HL; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Zhu LL; CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Zhang LK; University of Chinese Academy of Sciences, Beijing, 100049, China.
  • Bai F; School of Life Science and Technology, and Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, 201210, China.
Acta Pharmacol Sin ; 43(2): 483-493, 2022 Feb.
Article de En | MEDLINE | ID: mdl-33907306
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Antiviraux / Conception de médicament / SARS-CoV-2 Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Acta Pharmacol Sin Sujet du journal: FARMACOLOGIA Année: 2022 Type de document: Article Pays d'affiliation: Chine
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Antiviraux / Conception de médicament / SARS-CoV-2 Type d'étude: Prognostic_studies Limites: Animals / Humans Langue: En Journal: Acta Pharmacol Sin Sujet du journal: FARMACOLOGIA Année: 2022 Type de document: Article Pays d'affiliation: Chine